Sustained Drug Delivery in Retina

How do we reduce the injection burden for our #retina patients? 👁️💬 In this video, Dr. Mona Camacci discusses one of the biggest challenges in managing #AMD, diabetic retinopathy, and RVO: maintaining therapeutic anti-VEGF levels over time. She walks through: • Why drug levels drop after bolus injections • How this leads to fluid fluctuations and more frequent dosing • What retina specialists value most today: safety and durability • Current sustained-release options already in use • And the next big leap: gene therapy that may deliver long-term, continuous anti-VEGF expression These emerging therapies could completely change the treatment landscape and improve the lives of millions of patients. 🎥 Watch to hear Dr. Camacci’s perspective on where sustained delivery is headed. References: Hahn P, ed. ASRS 2025 Preferences and Trends Membership Survey. Chicago, IL: American Society of Retina Specialists; 2025